Andere Sprachen SCYNEXIS, Inc.

Aktien

A2P9T4

US8112922005

SCYX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 14.05.2024			% 5 Tage	% 1. Jan.
1,97 ^USD	-3,43 %		+6,78 %	-11,66 %

08.05.	SCYNEXIS, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
09.04.	SCYNEXIS, Inc. präsentiert präklinische Daten zum Fungerpen der zweiten Generation SCY-247 auf dem 34. Europäischen Kongress für klinische Mikrobiologie und Infektionskrankheiten	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M	08.05.
Scynexis: Q1 Earnings Snapshot	08.05.
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update	08.05.
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)	30.04.
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)	09.04.
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	09.04.
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update	28.03.
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference	30.01.
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference	29.01.
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference	29.01.
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	08.01.
SCYX DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX	07.01.
SCYX Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	07.01.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX	06.01.
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy	05.01.
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit	04.01.
SCYNEXIS Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options	04.01.
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SCYNEXIS, Inc.

Aktien

A2P9T4

US8112922005

SCYX

Andere Sprachen

Filter